Representatives of different groups of lipid-lowering drugs may have some differences in the nature and severity of the effect on the blood lipid spectrum. A new class of drugs, PCSK9 inhibitors, whose activity is associated with a protein involved in the control of low density lipoprotein receptors, has recently appeared. In clinical practice, this group is represented by monoclonal antibody preparations evolocumab and alirocumab. PCSK9 inhibitors are promising drugs for use in combination lipid-lowering therapy, which so far, given the results of clinical studies, can be recommended in the third place after statins and ezetimibe. In clinical studies, it was shown that alirocoumab and evolocumab alone or in combination with statins and/or other lipid-lowering drugs significantly reduce cholesterol levels in low density lipoproteins – by an average of 60%, depending on the dose.
During pharmacotherapy with neuroleptics of paranoid schizophrenia patients there had been studied retrospectively and perspectively frequency and expressiveness of side effects. There was determined a correlation between neuro-motor reaction expressiveness of neuroleptics and sex, age and time of intake. The obtained results can be very useful to a practioner for his/ her rational usage of psychotropic medications, removal of neuro- motor reaction and making decision in continuation of neuroleptic therapy.